BioSpace News Archive

Many researchers have found it necessary to transition from academia to industry to bring their therapeutic visions to fruition, but this change can be quite the culture shock.

The FDA accepted the BLA for and granted Pfizer’s maternal RSV vaccine candidate priority review.

Akebia Therapeutics announced another delay Tuesday in a series of setbacks for vadadustat, being developed to treat anemia linked to chronic kidney disease.

Artificial intelligence and machine learning could change the face of cancer diagnostics. BioSpace spoke with the University of Waterloo, Gina Life and OncoHost to find out how.

Actinium Pharmaceuticals’ Iomab-B met the primary endpoint in the Phase III SIERRA trial, demonstrating durable Complete Remission at six months.

NextPoint Therapeutics announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).

Peptilogics announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections on Monday, February 27, 2023 at 11 AM ET.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”) announces the appointment of Mr. Evan Ballantyne to the Company’s board of directors (the “Board”) effective February 17, 2023.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it signed an agreement with City of Hope National Medical Center and Beckman Research Institute of the City of Hope,

Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™ today announced it will report fourth quarter 2022 financial results prior to the market open on Monday, March 6, 2023.